What is PFE's House Rating?

PFE scores 35 out of 100 (grade D) as of 2026-10-16, ranking #56 of 150 Health Care stocks we cover.

What do analysts say about PFE?

ThetaGrade's analyst-sentiment pillar for PFE scores 17/100 against its sector peers, which we read as negative. This is our own derived score; we do not republish individual analyst ratings, counts or targets.

When does PFE report earnings next?

PFE's next earnings report is estimated for about 2026-11-03 (window 2026-10-27 to 2026-11-10), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.

ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

PFE Pfizer

Health Care · Pharmaceuticals · close $29.58 (2026-10-16) · latest quarter in EDGAR: 2026-06-28

#56/150 in sector · #420/964 overall

Pfizer (PFE) has a ThetaGrade House Rating of 35/100 (grade D), ranking #56 of 150 in Health Care. Its strongest pillars are cash flow (70) and profitability (58); its weakest is balance sheet (16). TTM revenue growth is -0.2% and operating margin 10.8%.

Data as of 2026-10-16.

Analyst sentiment

weight 7.5% · 17

Consensus score (1–5) (3.8%)	derived	3
90-day net rating shift (3.8%)	derived	49

Growth

weight 30.83% · 16

Revenue growth YoY (TTM) (12.3%)	-0.2%	9
EPS growth YoY (TTM) (12.3%)	-59.6%	16
Revenue acceleration (6.2%)	-2.8%	31

Profitability

weight 18.5% · 58

Operating margin (9.9%)	10.8%	45
4Q gross-margin change (8.6%)	1.1%	72

Balance sheet

weight 18.5% · 16

Net debt / EBITDA (9.9%)	4.60×	10
Current ratio (4.9%)	1.27	19
Interest coverage (3.7%)	2.59×	30

Cash flow

weight 12.33% · 70

FCF margin (6.2%)	14.5%	59
FCF yield (6.2%)	5.4%	81

Valuation

weight 12.33% · 49

P/E (inverted) (6.2%)	38.92×	34
EV/Sales (inverted) (6.2%)	3.62×	64

Technicals (EOD)

RSI(14)	69.7
EMA 9 / 21	28.77 / 28.39
200-day SMA	26.56
Volume vs 20d avg	0.87×
20-day return	7.0%

Exit-rule monitor

EXITRating break: House Rating below 60
EXITFundamental miss: revenue growth negative YoY
EXITBalance-sheet stress: net debt/EBITDA above 4×

Data source per metric (SEC XBRL tag or derivation): Revenue: Revenues · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: Pretax income + interest expense (EBIT proxy) · Interest expense: InterestExpense · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).

Get rating changes like PFE's in the free Daily Brief

The market’s key events and signals, digested before the open.

✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
✓ OPEX, FOMC, CPI and jobs-day reminders

Free. Want more? See Premium (waitlist).

FAQ

What is PFE's House Rating?: PFE scores 35 out of 100 (grade D) as of 2026-10-16, ranking #56 of 150 Health Care stocks we cover.
What do analysts say about PFE?: ThetaGrade's analyst-sentiment pillar for PFE scores 17/100 against its sector peers, which we read as negative. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
When does PFE report earnings next?: PFE's next earnings report is estimated for about 2026-11-03 (window 2026-10-27 to 2026-11-10), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
Is PFE a buy?: ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology